-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
Lost in Translation: Survey Reveals Critical Communication Gaps in Lung Cancer Care
Complex information and poor communication were identified as major obstacles to meaningful participation in decision-making, according to data presented by patient advocate Debra Montague.
-
EA5181 Confirms Durvalumab After CRT is SOC for Unresectable Stage III NSCLC
Dr. John Varlotto highlighted that the survival curves were ‘superimposable,’ showing no differences in median OS or PFS outcomes.
-
HypoRT with Concurrent Chemo Shows Favorable Safety Profile
Dr. Nan Bi said further investigation of HypoRT with immunotherapy is warranted based on these findings and potential immune-sparing benefits.
-
STAS is Associated with Poor Prognosis in Early-Stage NSCLC Regardless of Surgical Approach
JCOG0802/WJOG4607L data validate segmentectomy as non-inferior to lobectomy, regardless of the presence of STAS, Dr. Yasushi Yatabe said.
-
Novel Meta-Analysis Shows VATS Improves Overall Survival in Early-Stage Lung Cancer
Dr. Jacie Jiaqi Law shared results from a first-ever meta-analysis demonstrating that VATS reduces mortality risk without compromising disease-free survival.
-
New Data Warrant Broader Lung Cancer Screening Guidelines
Dr. Elaine Shum said the FANSS trial data confirm the feasibility of expanding screening to high-risk individuals with no smoking history.
-
Survival Benefit Found in Screening Surgically Fit Patients Up to Age 80
Findings from Dr. Patrick Goodley suggest that older patients who can undergo surgery may achieve survival benefits similar to younger patients.
-
Lessons from ECOG-ACRIN E4512: Could Limited Gains Lead to Positive Direction in Refining Adjuvant Therapy?
Discussant Dr. Jessica L. Lin said the results won’t change clinical practice after Dr. David Gerber reported no differences in OS or DFS.
-
IASLC Launches Career Advancement Grant to Expand Support for Mid-Career Researchers
By supporting multidisciplinary and global projects, the grant ensures mid-career professionals can continue contributing vital research to the field of lung and thoracic malignancies.
-
Ivonescimab-Chemotherapy Combo Shows Promise as Post-TKI Option in EGFR-Mutant NSCLC
Dr. Jonathan W. Goldman reported that ivonescimab plus chemotherapy yielded a consistent PFS benefit across subgroups.